Clincosm LogoSign in Get a demo

NDPH: New Daily Persistent Headache Survey

Sponsor
The University of Texas Health Science Center, Houston (Other)
Overall Status
Recruiting
CT.gov ID
NCT05984719
Collaborator
(none)
10,000
Enrollment
1
Location
14.4
Anticipated Duration (Months)
693.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Purpose: to explore headache characteristics and treatment effects of patient with new daily persistent headache (NDPH) through an online survey.

Research design: Online survey of patients with new daily persistent headache.

Risks: Risks include a breach of confidentiality as well as fatigue from taking the survey online.

Importance of knowledge that may recently be expected to result: The study aims to discover new information in a very understudied disease. This information could, in future studies, help change the diagnostic criteria or lead to new treatment options.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    10000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    New Daily Persistent Headache Patient Experience Survey
    Actual Study Start Date :
    Jun 19, 2023
    Anticipated Primary Completion Date :
    Feb 29, 2024
    Anticipated Study Completion Date :
    Aug 31, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    New daily persistent headache (NDPH) group

    Participants with NDPH will be administered an online survey.

    Outcome Measures

    Primary Outcome Measures

    1. Survey data [At study completion, expected to be in 6-12 months.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with NDPH that have been diagnosed by a health care professional (no documentation is needed, participant must simply state that he or she has been diagnosed)
    Exclusion Criteria:

    • Unable to speak English (the survey is only in English)

    • Unable to use a computer to take the online survey

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UTHealth Houston Houston Texas United States 77030

    Sponsors and Collaborators

    • The University of Texas Health Science Center, Houston

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Mark J Burish, Associate Professor, The University of Texas Health Science Center, Houston
    ClinicalTrials.gov Identifier:
    NCT05984719
    Other Study ID Numbers:
    • HSC-MS-23-0206
    First Posted:
    Aug 9, 2023
    Last Update Posted:
    Aug 9, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mark J Burish, Associate Professor, The University of Texas Health Science Center, Houston
    Constant headache
    Refractory headache disorder
    Additional relevant MeSH terms:
    Headache

    Study Results

    No Results Posted as of Aug 9, 2023